154 related articles for article (PubMed ID: 25232966)
1. Efficient synthesis of hexahydroindenopyridines and their potential as melatoninergic ligands.
Párraga J; Moreno L; Diaz A; El Aouad N; Galán A; Sanz MJ; Caignard DH; Figadère B; Cabedo N; Cortes D
Eur J Med Chem; 2014 Oct; 86():700-9. PubMed ID: 25232966
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of new melatoninergic hexahydroindenopyridines.
Moreno L; Berenguer I; Diaz A; Marín P; Párraga J; Caignard DH; Figadère B; Cabedo N; Cortes D
Bioorg Med Chem Lett; 2014 Aug; 24(15):3534-6. PubMed ID: 24930835
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.
Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C
Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity.
Couhert A; Delagrange P; Caignard DH; Chartier A; Suzenet F; Guillaumet G
Eur J Med Chem; 2016 Feb; 109():268-75. PubMed ID: 26785296
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
Hu Y; Chan KH; He X; Ho MK; Wong YH
PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
Attia MI; Witt-Enderby PA; Julius J
Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
[TBL] [Abstract][Full Text] [Related]
9. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
[TBL] [Abstract][Full Text] [Related]
11. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
[TBL] [Abstract][Full Text] [Related]
12. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
[TBL] [Abstract][Full Text] [Related]
14. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
15. New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization.
de la Fuente Revenga M; Herrera-Arozamena C; Fernández-Sáez N; Barco G; García-Orue I; Sugden D; Rivara S; Rodríguez-Franco MI
Eur J Med Chem; 2015 Oct; 103():370-3. PubMed ID: 26367450
[TBL] [Abstract][Full Text] [Related]
16. New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.
Ancizu S; Castrillo N; Pérez-Silanes S; Aldana I; Monge A; Delagrange P; Caignard DH; Galiano S
Molecules; 2012 Jun; 17(7):7737-57. PubMed ID: 22732886
[TBL] [Abstract][Full Text] [Related]
17. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
[TBL] [Abstract][Full Text] [Related]
19. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in melatonin receptor ligands.
Zlotos DP
Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
